Development and Validation of RCC Predicting Model With Emulated-target Trial

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Aug 11, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on kidney cancer, specifically a type called renal cell carcinoma (RCC). Researchers at Peking University Third Hospital are using health information from about 4,700 patients treated between 2012 and 2024 to create and test a new tool that can predict how well patients with RCC will do over time. This tool aims to help doctors understand a patient’s risk level—whether high, medium, or low—and decide the best treatment plan based on that risk. The study will also look at whether using this risk-based approach improves patients’ chances of survival, lowers the chance of cancer coming back, and provides good value in terms of health outcomes and costs compared to standard treatments that don’t consider individual risk.

Adults 18 years and older who have been diagnosed with RCC and have had surgery to remove the tumor are eligible to be part of this study. People with missing important health information or those who have had other types of cancer will not be included. While the study is not yet recruiting participants, those involved can expect their medical data to be used to test this new prediction tool and to see if personalized treatment based on risk helps improve their health outcomes. This study is important because it uses real-world patient information to develop a more tailored approach to treating kidney cancer, which could lead to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults ≥18 years of age;
• • Diagnosis of primary renal cell carcinoma before and during the surgery;
• • Received radical nephrectomy/nephron-sparing surgery.
• Exclusion Criteria:
• • Subjects with severely missing clinical information;
• • History of other malignant tumors.